You are here

cancer

JPM24: Even after Seagen buyout, Pfizer oncology chief still eyes ADC deals

Fierce Pharma

Thu, 01/11/24 - 11:34 am

antibody-drug conjugate

C4 lays off 30% of staff in aftermath of BRD9 degrader discontinuation

Fierce Biotech

Wed, 01/10/24 - 09:35 am

C4 Therapeutics

Cancer biotech ArriVent Biopharma files for a $100 million IPO

Renaissance Capital

Mon, 01/8/24 - 11:38 am

ArriVent Biopharma

Allogene to shift strategy in bid to reposition CAR-T

BioPharma Dive

Fri, 01/5/24 - 10:03 am

Allogene Therapeutics

Galapagos wants to find new small molecule species for cancer with BridGene

Fierce Biotech

Wed, 01/3/24 - 05:05 pm

BridGene Biosciences

small molecule drugs

Market for CAR-Ts Still Bright Despite FDA Cancer Safety Review

BioSpace

Wed, 12/20/23 - 09:36 am

Oncologists Defend CAR-T After FDA Advisory

BioSpace

Mon, 12/18/23 - 10:11 am

Bicycle Therapeutics Provides Data Updates for Three Clinical Programs and Strategy Overview at First R&D Day

BioSpace

Fri, 12/15/23 - 09:43 am

Bicycle Therapeutics

Virtual twin to improve treatment with cancer immunotherapies

BioSpace

Thu, 12/14/23 - 09:31 am

personalized medicine

Pfizer donates rights to cancer drug

Beckers Hospital Review

Wed, 12/13/23 - 09:39 am

Bristol Myers pays SystImmune $800M and adds to pharma’s ‘ADC’ deal spree

BioPharma Dive

Tue, 12/12/23 - 09:58 am

Bristol Myers Squibb

antibody-drug conjugate

Oncology drugmakers seek the sweet spot between efficacy and tolerability

Pharma Voice

Mon, 12/11/23 - 10:16 am

drug development

Moderna, Merck begin late-stage study for mRNA cancer therapy

Reuters

Mon, 12/11/23 - 10:00 am

Moderna Therapeutics

clinical trials

Dupixent for cancer? Researchers test blockbuster med as an immunotherapy-booster

Fierce Biotech

Thu, 12/7/23 - 11:13 pm

CRISPR eyes autoimmune disease in revamp of cell therapy plans

BioPharma Dive

Tue, 12/5/23 - 11:38 am

CRISPR Therapeutics

autoimmune disease

AstraZeneca, AI biologics firm Absci tie up on cancer drug

Reuters

Sun, 12/3/23 - 09:31 pm

artificial intelligence

Merck turns to Acclinate to increase African American participation in cancer trials

Fierce Biotech

Thu, 11/30/23 - 09:52 am

clinical trials

clinical trial diversity

BeiGene Inks Potential $1.3B Deal with Ensem for Early-Stage CDK2 Inhibitor

BioSpace

Tue, 11/21/23 - 11:54 am

Gilead Oncology’s brand refresh takes back the possibilities cancer steals

Medical Marketing and Media

Mon, 11/20/23 - 09:36 pm

Gilead Oncology

FDA's oncology office uses advisory committee to spotlight timely accelerated approval confirmation

Fierce Pharma

Wed, 11/15/23 - 11:20 am

accelerated approvals

Acrotech Biopharma

Pages